Rallybio and Avenzo Merge to Advance Oncology Pipeline with $215M Financing
NEW HAVEN, Conn. & SAN DIEGO, Calif., June 2, 2026 Rallybio Corporation and Avenzo Therapeutics announced a definitive merger...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
NEW HAVEN, Conn. & SAN DIEGO, Calif., June 2, 2026 Rallybio Corporation and Avenzo Therapeutics announced a definitive merger...
WAYNE, Pa., May 21, 2026 Palvella Therapeutics announced that it has been named Healthcare & Life Sciences Company of...
ENCINITAS, Calif., May 11, 2026 Vasa Therapeutics, a clinical-stage biotechnology company focused on therapies targeting cardiovascular and metabolic aging,...
New York, United States & Waltham, Massachusetts – March 9, 2026 Dianthus Therapeutics, Inc., a clinical-stage biotechnology company focused...
LONDON, U.K., Feb. 23, 2026 — Hemogenyx Pharmaceuticals PLC announced the exercise of warrants and subsequent issue of new...
Lille & Paris, France — February 10, 2026: 4Moving Biotech (4MB), a clinical-stage biotechnology company and spin-off of 4P-Pharma,...
BOTHELL, Wash., Feb. 6, 2026 — Immunome, Inc., a clinical-stage biotechnology company developing targeted oncology therapeutics, announced that its...
SPRING HOUSE, Pa., Feb. 4, 2026 — Clinical-stage biotechnology company Third Arc Bio announced the closing of a $52...
